EZETIMIBE - Generic Drug Details

What are the generic drug sources for ezetimibe and what is the scope of patent protection?

Ezetimibe is the generic ingredient in five branded drugs marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Ohm Labs Inc, Orient Pharma, Rising, Sandoz, Sciegen Pharms, Teva Pharms Usa, Watson Labs Inc, Zydus Pharms, Organon, Althera Pharms, Ani Pharms, Aurobindo Pharma Usa, Dr Reddys Labs Sa, and Torrent, and is included in twenty-eight NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ezetimibe has two hundred and thirty-five patent family members in thirty-eight countries.

There are twenty-four drug master file entries for ezetimibe. Twenty-five suppliers are listed for this compound.

Summary for EZETIMIBE

International Patents:	235
US Patents:	3
Tradenames:	5
Applicants:	22
NDAs:	28
Drug Master File Entries:	24
Finished Product Suppliers / Packagers:	25
Raw Ingredient (Bulk) Api Vendors:	113
Clinical Trials:	386
Drug Prices:	Drug price trends for EZETIMIBE
Drug Sales Revenues:	Drug sales revenues for EZETIMIBE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EZETIMIBE
What excipients (inactive ingredients) are in EZETIMIBE?	EZETIMIBE excipients list
DailyMed Link:	EZETIMIBE at DailyMed

See drug prices for EZETIMIBE

See drug sales revenues for EZETIMIBE

Recent Clinical Trials for EZETIMIBE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yuhan Corporation	NA
Beijing Tiantan Hospital	NA
Severance Hospital	NA

See all EZETIMIBE clinical trials

Pharmacology for EZETIMIBE

Drug Class	Dietary Cholesterol Absorption Inhibitor
Physiological Effect	Decreased Cholesterol Absorption

Medical Subject Heading (MeSH) Categories for EZETIMIBE

Anticholesteremic Agents

Anatomical Therapeutic Chemical (ATC) Classes for EZETIMIBE

C10AX	Other lipid modifying agents
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for EZETIMIBE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZETIA	Tablets	ezetimibe	10 mg	021445	1	2006-10-25

US Patents and Regulatory Information for EZETIMIBE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	EZETIMIBE	ezetimibe	TABLET;ORAL	210859-001	Jul 26, 2022	AB	RX	No	No
Rising	EZETIMIBE	ezetimibe	TABLET;ORAL	201790-001	Apr 26, 2019		DISCN	No	No
Alkem Labs Ltd	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	209222-003	Dec 22, 2017	AB	RX	No	No
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-001	Mar 23, 2021		DISCN	Yes	No			Y
Zydus Pharms	EZETIMIBE	ezetimibe	TABLET;ORAL	204331-001	Jun 12, 2017	AB	RX	No	No
Sciegen Pharms	EZETIMIBE	ezetimibe	TABLET;ORAL	210673-001	Oct 23, 2020	AB	RX	No	No
Althera Pharms	ROSZET	ezetimibe; rosuvastatin calcium	TABLET;ORAL	213072-003	Mar 23, 2021		DISCN	Yes	No			Y

Expired US Patents for EZETIMIBE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	ZETIA	ezetimibe	TABLET;ORAL	021445-001	Oct 25, 2002

International Patents for EZETIMIBE

Country	Patent Number	Title	Estimated Expiration
Argentina	032403	COMBINACIONES DE INHIBIDOR(ES) DE LA ABSORCION DE ESTEROL CON MODIFICADOR(ES) SANGUINEOS PARA TRATAR CUADROS VASCULARES
Argentina	032643	COMBINACIONES DE INHIBIDOR(ES) DE ABSORCION DE ESTEROL CON AGENTE(S) CARDIOVASCULAR(ES) PARA EL TRATAMIENTO DE CONDICIONES VASCULARES
Argentina	033855	COMPOSICIONES Y COMBINACIONES DE ACTIVADOR(ES) DEL RECEPTOR DE ACTIVACION DE PROLIFERACION PEROXIS0MAL (PPAR) E INHIBIDOR(ES) DE ABSORCION DE ESTEROL, EL USO DE DICHAS COMPOSICIONES O COMBINACIONES PARA LA MANUFACTURA DE UN MEDICAMENTO PARA EL TRATAMIENTO PARA INDICACIONES VASCULARES, DIABETES, OBES
Argentina	034204	COMPOSICIONES Y COMBINACIONES DE ACIDO NICOTINICO Y DERIVADOS DEL MISMO CON INHIBIDOR(ES) DE LA ABSORCION DE LOS ESTEROLES, Y EL USO DE LOS MISMOS PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO PARA INDICACIONES VASCULARES
Argentina	035611	2 -AZETIDINONAS SUSTITUIDAS CON AZUCARES, COMPOSICION FARMACEUTICA, UN KIT, USO DE DICHOS COMPUESTOS PARA LA FABRICACION DE MEDICAMENTOS UTILES COMO AGENTES HIPOCOLESTEROLEMICOS.
Argentina	035739	COMPOSICIONES FARMACEUTICAS Y COMBINACIONES TERAPEUTICAS QUE COMPRENDEN SECUESTRANTE (S) DE LOS ACIDOS BILIARES Y DE INHIBIDOR (ES) DE LA ABSORCION DE LOS ESTEROLES Y EL USO DE DICHAS COMPOSICIONES PARA LA MANUFACTURA DE UN MEDICAMENTO PARA EL TRATAMIENTO DE INDICACIONES VASCULARES
Argentina	064012	COMPOSICIONES Y COMBINACIONES DE ACTIVADOR(ES) DEL RECEPTOR DE ACTIVACION DE PROLIFERACION PEROXISMAL (PPAR) E INHIBIDOR(ES) DE ABSORCION DE ESTEROL EL USO DE DICHAS COMPOSICIONES PARA LA MANUFACTURA DE UN MEDICAMENTO PARA EL TRATAMIENTO PARA INDICACIONES VASCULARES DIABETES OBESIDAD O REDUCCION DE

Supplementary Protection Certificates for EZETIMIBE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	C300132	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION: RVG 28626 20030418; FIRST REGISTRATION: DE 54486.00.00, 54487.00.00, 54488.00.00, 54489.00.00 20021017
0720599	03C0028	France		PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017
0720599	300689	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
0720599	92544	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724
0720599	05C0040	France		PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
0720599	SPC/GB05/010	United Kingdom		PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
0720599	C300688	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NAT. REGISTRATION NO/DATE: RVG114002-004RVG 114008-010 2014110811; FIRST REGISTRATION: 13-9663 - 9665 20140724

Ezetimibe (EZETIMIBE) Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What drives the ezetimibe market today?

Ezetimibe is an oral lipid-lowering drug used primarily for cholesterol management, most commonly in combination with statins and other lipid agents. The commercial market structure is shaped by (1) statin-anchored lipid therapy, (2) entrenched payer formularies and guideline adoption, (3) generic entry and price compression, and (4) manufacturer mix across geographies.

Key demand drivers

• Chronic condition, ongoing therapy: Indication use is tied to long-term cardiovascular risk management rather than episodic treatment.
• Combination regimens with statins: Ezetimibe’s standard market position is add-on therapy when statin response is insufficient or not tolerated, supporting sustained demand even as monotherapy use fluctuates.
• Guideline alignment: Clinical guidelines support ezetimibe use in specific risk strata and treatment intensification pathways, supporting continued payer coverage.
• Evolving lipid management pathways: Growth in cardiovascular prevention programs supports volume stability, while incremental penetration depends on payer step edits and competing non-statin classes.

Key supply and pricing drivers

• Generic-led price compression: Once oral small-molecule generics enter, net pricing typically declines quickly, shifting the revenue model toward volume scale and low-cost procurement.
• Formulation and brand portfolio turnover: Brand-only revenue is capped by generic availability; manufacturers must rely on geography, contractual pricing, and mix-shifts to sustain value.
• Competitive class pressure: Ezetimibe competes indirectly with newer lipid agents (e.g., PCSK9 inhibitors, bempedoic acid in certain markets) where payers steer high-risk patients toward higher-cost pathways.

How is the product positioned versus alternatives?

Ezetimibe sits in the non-statin ecosystem as a lower-cost add-on that can be used broadly at earlier points in the lipid-risk management pathway compared with high-cost injectable therapies.

Competitive set (commercial lens)

• Statins: Typically first-line; ezetimibe captures “insufficient response” and intolerance-driven step-up segments.
• Other non-statin oral agents: Competes for formulary placement based on incremental LDL-C reduction, tolerability profile, and payer cost-effectiveness.
• Injectables (e.g., PCSK9 inhibitors): Higher-priced and used in narrower, high-risk segments; they can reduce incremental demand growth for ezetimibe in those segments when payers restrict access.

What does the financial trajectory look like across a typical lifecycle?

Ezetimibe’s financial trajectory is dominated by the transition from brand-led penetration to generic-led volume and pricing normalization.

Lifecycle pattern for ezetimibe economics

1. Early growth / brand scaling
   • Establishes guideline use and payer acceptance.
   • Revenue is supported by branded pricing and protected market access in early years.
2. Patent expiry and generic entry
   • Net prices decline as branded share is replaced by generics.
   • Revenue becomes volume-driven and tends to flatten or contract in nominal terms.
3. Mature generic market
   • Market growth mainly follows underlying cardiovascular patient pool and adherence.
   • Value growth depends on brand persistence in certain geographies, distribution concentration, and payer mix.

Where does ezetimibe revenue concentrate geographically?

Ezetimibe revenue is generally shaped by generic adoption timelines and payer formulary behavior across major markets. In mature categories, revenue tends to concentrate where generic availability is broad and where reimbursement is stable.

Market concentration logic

• US: Large generic participation tends to compress unit economics, but high volume supports continued category revenue.
• EU5 (France, Germany, Italy, Spain, UK): Formularies and generic penetration shape price declines; prescribing patterns influence relative stability.
• Japan and other developed markets: Longer brand persistence in some cases can extend nominal revenues, but generic normalization still dominates long-run trend.

What has happened to competition and pricing after generic entry?

In mature oral small-molecule markets, generic penetration usually results in:

• Rapid decline in branded unit prices
• Shift to multi-source generic bidding
• Increased role for distribution scale and contract manufacturing economics
• Ongoing promotional pressure in remaining brand pockets

Ezetimibe follows that standard pattern because the asset is a small-molecule with broad therapeutic interchange and mature regulatory status.

How do payers typically influence utilization and net sales?

Payer controls influence utilization via:

• Step edits (statin first; ezetimibe add-on where criteria met)
• Prior authorization triggers for non-statin add-ons when criteria require documented LDL-C levels or statin intolerance
• Formulary tiering that determines out-of-pocket friction and adherence

In practice, net sales performance correlates with how easily patients pass payer criteria and how often clinicians intensify therapy without switching to alternate classes.

What is the likely medium-term financial outlook?

The medium-term trajectory is driven by two opposing forces:

• Volume stability: Patient pool for chronic lipid management supports baseline demand.
• Continued net price pressure: Generic competition and ongoing tender-driven pricing keep value growth constrained.

As newer lipid agents gain access in high-risk segments, ezetimibe’s incremental growth depends on payer willingness to sustain ezetimibe as an add-on rather than forcing escalation to higher-cost alternatives early.

---

Market and financial trajectory summary (business view)

Trajectory by stage

Lifecycle stage	Dominant revenue driver	Typical market behavior	Financial profile
Brand scaling	Differentiated access and premium pricing	Rapid uptake with payer adoption	Faster nominal growth
Generic transition	Price compression and share migration	Generic-driven unit decline	Nominal revenue flattening
Mature generic market	Volume and contracting	Tender-driven pricing stability	Low single-digit nominal growth or contraction

What to watch for

• Formulary status changes in major markets (tier movement, PA tightening)
• Generic tender dynamics affecting net prices
• Relative class access for PCSK9 inhibitors and other non-statin agents
• Patent and exclusivity events for brand or combination formats in specific geographies

---

Key Takeaways

• Ezetimibe market demand is anchored to chronic cardiovascular prevention and statin add-on use, with payer step edits shaping utilization.
• Financial performance follows a classic small-molecule lifecycle: branded scaling then generic-led price compression, shifting the model toward volume and contractual pricing.
• Medium-term growth is constrained by multi-source competition, while upside depends on payer persistence in ezetimibe add-on pathways and mix stability across geographies.
• Competitive substitution risk is real as payers steer higher-risk patients toward higher-efficacy, higher-cost lipid agents.

FAQs

1. What is ezetimibe’s main commercial use case?
   It is used as an oral lipid-lowering add-on, most often with statins, to improve LDL-C reduction in patients who need additional lowering or cannot tolerate higher statin doses.

2. What typically happens to ezetimibe pricing after generic entry?
   Net pricing usually declines sharply as branded units lose share to generics, and contracts shift to lowest-cost multi-source supply.

3. Why does payer policy matter so much for ezetimibe sales?
   Step edits and prior authorization determine whether clinicians can intensify therapy quickly, which directly affects patient volume and adherence.

4. Does ezetimibe face direct competition from newer lipid drugs?
   Indirectly. It competes for formulary placement within non-statin pathways, but newer agents often target higher-risk segments with different access criteria.

5. What is the most likely driver of future ezetimibe revenue?
   It is volume stability in chronic lipid management, tempered by ongoing generic price pressure and payer-driven substitution dynamics.

---

References

[1] FDA. “Zetia (ezetimibe).” FDA Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/ (accessed 2026-04-24).
[2] EMA. “Zetia: EPAR - Product Information.” European Medicines Agency. https://www.ema.europa.eu/ (accessed 2026-04-24).
[3] NICE. “Cardiovascular disease: risk assessment and management (lipid management guidance).” National Institute for Health and Care Excellence. https://www.nice.org.uk/ (accessed 2026-04-24).
[4] ESC/EAS. “2019 Guidelines for the management of dyslipidaemias.” European Society of Cardiology/European Atherosclerosis Society. European Heart Journal. (accessed 2026-04-24).